All In Biotech

Drug Trial Radar · NCT06463665

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

A Randomized Phase 2 Study Assessing the Efficacy and Safety of Olvimulogene Nanivacirepvec Followed by Platinum-doublet Chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor Compared With Docetaxel in Patients With NSCL Cancer After First Progression While on Front-line Immune Checkpoint Inhibitor-based Maintenance

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 142 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

142

Planned (sponsor's estimate)

Start

Sep 26, 2024

Primary completion

Feb 2027

Study completion Jul 2029

Sponsor

Lead sponsor
Genelux CorporationIndustry
Sponsor type
Industry
Collaborators
Newsoara Biopharma Co., Ltd.
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet chemotherapy + Physician's Choice of Immune Checkpoint Inhibitor (ICI) vs. docetaxel for patients with advanced or metastatic NSCLC who have shown first disease progression (i.e., progressive disease not yet confirmed by further scan after initial scan showing progression) while on front-line treatment or maintenance ICI therapy after front-line treatment with platinum-doublet chemotherapy + ICI as standard of care.

Conditions

  • Advanced Non-squamous Non-small-cell Lung Cancer
  • Advanced Squamous Non-Small Cell Lung Carcinoma
  • Metastatic Non-squamous Non Small Cell Lung Cancer
  • Metastatic Squamous Non-Small Cell Lung Carcinoma
  • Non-small Cell Lung Cancer
  • Non-small Cell Lung Cancer Stage III
  • Non-small Cell Lung Cancer Stage IV
  • Non-small Cell Lung Cancer Recurrent

Interventions

  • Olvimulogene nanivacirepvecBiological

    Olvi-Vec is an engineered oncolytic vaccinia virus

  • Platinum chemotherapy: carboplatin or cisplatinDrug

    Administered according to local practice.

  • Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLCDrug

    Administered according to local practice.

  • Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumabDrug

    Administered according to local practice.

  • DocetaxelDrug

    Administered according to local practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Blinded Independent Central Review (BICR)Time frame: From date of randomization up to 12 months.

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Pioneer Research Center, LLC

    Bullhead City, Arizona · Recruiting

  • Clermont Oncology Center

    Clermont, Florida · Recruiting

  • Oncology & Hematology Associates of West Broward

    Coral Springs, Florida · Recruiting

  • Helios Clinical Research

    Fort Lauderdale, Florida · Recruiting

  • Bioresearch Partner

    Hialeah, Florida · Recruiting

  • University of Miami - Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Bioresearch Partner

    Miami, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Recruiting

  • BRCR Medical Center, Inc.

    Plantation, Florida · Recruiting

  • Michigan Hematology and Oncology Consultants

    Dearborn, Michigan · Recruiting

  • Oakland Medical Group

    Farmington Hills, Michigan · Recruiting

  • Inspira Medical Center Mullica Hill

    Mullica Hill, New Jersey · Recruiting

  • Gabrail Cancer and Research Center

    Canton, Ohio · Recruiting

  • Texas Oncology - Austin Central

    Austin, Texas · Recruiting

  • World Research Link

    Baytown, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.